Novartis Buys Avidity: A $12 Billion Muscle Move
Update: 2025-10-26
Description
Novartis drops $12 billion to snag Avidity Biosciences, aiming to dominate rare muscle disorder treatments! Find out how this massive deal fortifies Novartis' drug pipeline, navigates US market challenges, and spins off a new cardiology company. Is this the future of pharma innovation?
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
